D.A. Davidson & Co. Bristol Myers Squibb CO Transaction History

D.A. Davidson & Co.

$12 Billion
Q3 2024

A detailed history of D.A. Davidson & Co. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, D.A. Davidson & Co. holds 378,934 shares of BMY stock, worth $21.3 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

378,934

Previous 415,115 8.72%

Holding current value

$21.3 Million

Previous $17.2 Million 13.75%

% of portfolio

0.16%

Previous 0.15%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$39.66 - $51.75 $1.43 Million - $1.87 Million	-36,181 Reduced 8.72%	378,934 $19.6 Million
Q2 2024 Jul 31, 2024	BUY	$40.25 - $52.99 $1.51 Million - $1.99 Million	37,496 Added 9.93%	415,115 $17.2 Million
Q1 2024 May 13, 2024	BUY	$47.98 - $54.4 $3.79 Million - $4.3 Million	79,035 Added 26.47%	377,619 $20.5 Million
Q4 2023 Feb 09, 2024	SELL	$48.48 - $57.85 $1.08 Million - $1.29 Million	-22,365 Reduced 6.97%	298,584 $15.3 Million
Q3 2023 Nov 08, 2023	BUY	$57.89 - $64.73 $693,522 - $775,465	11,980 Added 3.88%	320,949 $18.6 Million
Q2 2023 Aug 10, 2023	BUY	$63.71 - $70.74 $271,532 - $301,493	4,262 Added 1.4%	308,969 $19.8 Million
Q1 2023 Apr 25, 2023	BUY	$65.71 - $74.53 $682,201 - $773,770	10,382 Added 3.53%	304,707 $21.1 Million
Q4 2022 Feb 03, 2023	BUY	$68.48 - $81.09 $314,528 - $372,446	4,593 Added 1.59%	294,325 $21.2 Million
Q3 2022 Nov 07, 2022	BUY	$0.13 - $76.84 $319 - $188,872	2,458 Added 0.86%	289,732 $20.6 Million
Q2 2022 Jul 28, 2022	SELL	$72.62 - $79.98 $675,874 - $744,373	-9,307 Reduced 3.14%	287,274 $22.1 Million
Q1 2022 May 12, 2022	SELL	$61.48 - $73.72 $540,163 - $647,703	-8,786 Reduced 2.88%	296,581 $21.7 Million
Q4 2021 Jan 31, 2022	SELL	$53.63 - $62.52 $151,665 - $176,806	-2,828 Reduced 0.92%	305,367 $19 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $31,596 - $37,011	-534 Reduced 0.17%	308,195 $18.2 Million
Q2 2021 Aug 10, 2021	SELL	$61.91 - $67.42 $1.86 Million - $2.03 Million	-30,074 Reduced 8.88%	308,729 $20.6 Million
Q1 2021 May 07, 2021	BUY	$59.34 - $66.74 $4.78 Million - $5.37 Million	80,518 Added 31.17%	338,803 $21.4 Million
Q4 2020 Feb 10, 2021	SELL	$57.74 - $65.43 $14,088 - $15,964	-244 Reduced 0.09%	258,285 $16 Million
Q3 2020 Nov 02, 2020	BUY	$57.43 - $63.64 $847,551 - $939,199	14,758 Added 6.05%	258,529 $15.6 Million
Q2 2020 Aug 10, 2020	SELL	$54.82 - $64.09 $4.24 Million - $4.95 Million	-77,301 Reduced 24.08%	243,771 $14.3 Million
Q1 2020 May 05, 2020	BUY	$46.4 - $67.43 $1.16 Million - $1.68 Million	24,904 Added 8.41%	321,072 $17.9 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $1.71 Million - $2.24 Million	34,823 Added 13.32%	296,168 $19 Million
Q3 2019 Nov 05, 2019	BUY	$42.77 - $50.71 $875,544 - $1.04 Million	20,471 Added 8.5%	261,345 $13.3 Million
Q2 2019 Aug 13, 2019	BUY	$44.62 - $49.34 $443,879 - $490,834	9,948 Added 4.31%	240,874 $10.9 Million
Q1 2019 May 13, 2019	BUY	$45.12 - $53.8 $898,564 - $1.07 Million	19,915 Added 9.44%	230,926 $11.2 Million
Q4 2018 Jan 29, 2019	BUY	$48.76 - $63.23 $148,425 - $192,472	3,044 Added 1.46%	211,011 $11 Million
Q3 2018 Nov 13, 2018	SELL	$55.19 - $62.25 $83,833 - $94,557	-1,519 Reduced 0.73%	207,967 $12.9 Million
Q2 2018 Aug 02, 2018	BUY	$50.53 - $62.98 $258,511 - $322,205	5,116 Added 2.5%	209,486 $11.6 Million
Q1 2018 May 04, 2018	BUY	$59.92 - $68.98 $244,054 - $280,955	4,073 Added 2.03%	204,370 $12.9 Million
Q4 2017 Feb 08, 2018	SELL	$59.94 - $65.35 $329,190 - $358,902	-5,492 Reduced 2.67%	200,297 $12.3 Million
Q3 2017 Nov 08, 2017	BUY	$55.23 - $63.74 $900,801 - $1.04 Million	16,310 Added 8.61%	205,789 $13.1 Million
Q2 2017 Aug 11, 2017	BUY	N/A	189,479	189,479 $0

Others Institutions Holding BMY

# of Institutions

2,533

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $120B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.

Account